Exelixis stock dropped 14.5% after the biotech company gave a negative update on one of its candidate treatments. Exelixis had been working with Roche Group's …
Bruce E. Johnson, MD, FASCO Dana-Farber Cancer Institute Disclosures: …
LOS ANGELES, Aug. 12— Shares of Genentech Inc., the nation's largest biotechnology company, dropped today to their lowest level this year amid speculation that the company's heart attack drug, Activase, may face tough competition …
NEW YORK (CNNMoney.com) - Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006. The biotech, based in South San Francisco, also said it expects to …
Since Roche announced its intention to buy the outstanding shares of Genentech, everbody’s been wondering whether the company’s top scientists will bolt. Genentech put a retention plan in place yesterday — but the main payouts would …
"We were wrong," H.C. Wainwright's Debjit Chattopadhyay acknowledged in a target price revision, lowering his 12-month target on the stock to $19 from $33 and ...
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares in the world's second …
Genentech stock came under pressure Thursday morning after the firm invited analysts to the briefing. The stock closed off 25 cents, to $26.75, on the New York Stock Exchange. The announcement of free treatment for some patients …